Navigation Links
Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
Date:2/7/2013

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf=Astoria in New York City.

Carl Spana , Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs on Monday, February 11, 2013 at 11:00 a.m. ET.

Palatin Technologies has reported positive top-line results in its recently completed Phase 2B clinical trial with bremelanotide for treatment of female sexual dysfunction, and is preparing for an end-of-Phase 2 meeting with the Food and Drug Administration in anticipation of commencing Phase 3 trials. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through February 18, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
7. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
9. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
10. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
11. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 (PRWEB) June 18, 2013 ... and attendance system in North America, has introduced ... employee data and payroll records between ExakTime’s software ... automates ExakTime software setup and keeps employee ... employee data from a business’ current payroll software, ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 DuPont welcomes ... the 11th annual DuPont National AgriScience Teachers Ambassador Academy ... in Chestertown, Md. , The NATAA ... DuPont and is a special project of the ... of Agricultural Educators (NAAE) . The highly recommended ...
(Date:6/18/2013)... , June 18, 2013  regulated information — Global ... Klauk today announced the launch of a new ... ones. The Pledge empowers the ... stand and make a personal commitment to demand more: ... health care team and additional partial-onset seizure control.  More ...
(Date:6/18/2013)... ZIONA, Israel , June 18, 2013 ... complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, ... announced today that the company has been granted a ... indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate Compounds ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2
... p.m. (Pacific Time); ... http://www.adventrx.com , SAN DIEGO, March 13 ADVENTRX ... on in-licensing,developing and commercializing proprietary product candidates primarily for,the ... for the fourth quarter and year ended December 31, ...
... Brussels: THR), a biotechnology company focused on vascular,diseases, ... results for,the twelve month period ending 31 December ... to invest in its development,pipeline and has continued ... Highlights, - Successful placing of a total ...
... CITY, Mo., March 13 Proteon,Therapeutics, Inc. ( ... been issued by the European Patent Office. The ... of proteins known as elastases for,dilating arteries and ... related,United States patents in June and December of ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 7ThromboGenics Announces 2007 Full Year Results 2ThromboGenics Announces 2007 Full Year Results 3ThromboGenics Announces 2007 Full Year Results 4Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins 2
(Date:6/19/2013)... , June 19, 2013   ... clinical laboratory diagnostics technology for conducting on-demand, ... diabetes testing, as well as analysis of ... and platelet counts. The new system enables ... lab results for physicians and their patients, ...
(Date:6/19/2013)... patients who received injections of steroids contaminated with ... Compounding Center has found that some patients had ... a worsening of their symptoms and that magnetic ... among those individuals who received injections from highly ... an editorial by UC Davis Assistant Professor of ...
(Date:6/19/2013)... In the cover story for the journal Genetics ... the University of Massachusetts Amherst describe a new experimental ... the function of individual proteins in individual cell types ... allow deeper insights into protein function, Chase says, "because ... that single protein does when we isolate its function ...
Breaking Biology News(10 mins):Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 3Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 4Evolution of an outbreak: Complications from contaminated steroid injections 2UMass Amherst researchers develop powerful new technique to study protein function 2UMass Amherst researchers develop powerful new technique to study protein function 3
... 1, 2007A new Joslin-led study has shown that leptin, ... energy metabolism, plays a major role in islet cell ... new avenues for studying leptin and its role in ... for diabetes. This study appears in the October ...
... Engineers at Washington University in St. Louis are finding ... the heart during embryonic development. Larry A.Taber, ... Engineering, and Phillip Bayly, Ph.D., Hughes Professor of Mechanical ... in the folding of the brains surface, or cortex, ...
... , The New York Academy of Sciences, 7 World ... NY 10007 The Malaria Research Institute at the ... New York Academy of Sciences present Progress Against Malaria: ... the latest research developments in the fight to combat ...
Cached Biology News:Joslin researchers uncover potential role of leptin in diabetes 2Engineers study brain folding in higher mammals 2Engineers study brain folding in higher mammals 3Progress Against Malaria: Developments on the Horizon 2
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: